Combination antiangiogenic therapy and radiation in head and neck cancers

Oral Oncology

Volumn 50, Issue 1, 2014, Pages 19-26

  Hsu, Heng Wei ^a,b   Wall, Nathan R ^a   Hsueh, Chung Tsen ^b   Kim, Seungwon ^c   Ferris, Robert L ^c   Chen, Chien Shing ^a,b   Mirshahidi, Saied ^a,b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antiangiogenesis; Comibination therapy; DNA damage; Head and neck cancer; Radiation; Targeted therapy; VEGFR PDGFR inhibitor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; HYDROXYUREA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LINIFANIB; MATRIX METALLOPROTEINASE; MOTESANIB; PLACENTAL GROWTH FACTOR; SORAFENIB; STAT3 PROTEIN; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BONE NECROSIS; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; DEHYDRATION; DNA DAMAGE; DRUG FATALITY; DYSPHAGIA; FATIGUE; GLIOBLASTOMA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; INTENSITY MODULATED RADIATION THERAPY; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SORE THROAT; STOMATITIS; THYROID CANCER; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

5-FLUOROURACIL, HYDROXYUREA, RADIOTHERAPY; AA; AKT; ANTIANGIOGENESIS; ANTIANGIOGENIC AGENT; CA; CARBONIC ANHYDRASE; CCRT; CI; COMIBINATION THERAPY; CONCURRENT CHEMORADIATION; CONFIDENCE INTERVAL; COX; CYCLOOXYGENASE; DNA DAMAGE; EBV; EGF/R; EPIDERMAL GROWTH FACTOR/RECEPTOR; EPSTEIN-BARR VIRUS; ERCC; EXCISION-REPAIR CROSS-COMPLEMENTING PROTEIN; FETAL LIVER KINASE; FGF; FHX; FIBROBLAST GROWTH FACTOR; FLK; FLT; FMS-LIKE TYROSINE KINASE; GLUCOSE TRANSPORTER; GLUT; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIF; HNSCC; HPV; HUMAN PAPILLOMA VIRUS; HYPOFRACTIONATED IMAGE-GUIDED RADIOTHERAPY; HYPOXIA-INDUCING FACTOR; IFP; IGRT; IMRT; INTENSITY MODULATED RADIOTHERAPY; INTERSTITIAL FLUID PRESSURE; KDR; KINASE INSERT DOMAIN RECEPTOR; KIT; MAMMALIAN TARGET OF RAPAMYCIN; MAPK; MATRIX METALLOPROTEINASE; MITOGEN-ACTIVATED PROTEIN KINASE; MMP; MTOR; NASOPHARYNGEAL CARCINOMA; NPC; OSR; OVERALL SURVIVAL RATE; PDGF/R; PFR; PHOSPHOINOSITIDE 3-KINASE; PI3K; PLACENTA GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR/RECEPTOR; PLGF; PROGRESSION FREE RATE; PROTEIN KINASE B; RADIATION; RT; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; STAT; STEM CELL FACTOR RECEPTOR; TARGETED THERAPY; TKI; TYROSINE KINASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR/RECEPTOR; VEGF/R; VEGFR/PDGFR INHIBITOR; X-RAY REPAIR CROSS-COMPLEMENTING PROTEIN; XRCC;

ANGIOGENESIS INHIBITORS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 84890549535     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.10.003     Document Type: Review

References (97)

1. D. Saman A review of the epidemiology of oral and pharyngeal carcinoma: update Head Neck Oncol 4 2012 1 7
2. M. Gillison, T. Broutian, R. Pickard, Z. Tong, W. Xiao, and L. Kahle Prevalence of oral hpv infection in the united states, 2009-2010 JAMA 307 7 2012 693 703
3. S.K. Kundu, and M. Nestor Targeted therapy in head and neck cancer Tumor Biol 33 3 2012 707 721
4. V.W.Y. Lui, E.Y.L. Wong, Y. Ho, B. Hong, S.C.C. Wong, and Q. Tao STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro Int J Cancer 125 8 2009 1884 1893
5. Y. Ho, S.W. Tsao, M. Zeng, and V.W.Y. Lui STAT3 as a therapeutic target for Epstein-Barr virus (EBV) - associated nasopharyngeal carcinoma Cancer Lett 330 2 2013 141 149
6. Y.H. Tseng, K.W. Chang, C.C. Yang, C.J. Liu, S.Y. Kao, and T.Y. Liu Association between areca-stimulated vimentin expression and the progression of head and neck cancers Head Neck 34 2 2012 245 253
7. A. Forastiere, W. Koch, A. Trotti, and D. Sidransky Head and neck cancer N Engl J Med 345 26 2001 1890 1900 (Pubitemid 33716564)
8. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 6 2006 567 578 (Pubitemid 43209104)
9. Q. Pan, M.A. Gorin, and T.N. Teknos Pharmacotherapy of head and neck squamous cell carcinoma Expert Opin Pharmacol 10 14 2009 2291 2302
10. X. Yin, D.N. Hayes, and C.G. Shores Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma Head Neck 33 8 2011 1106 1114
11. N. Sahu, and J.R. Grandis New advances in molecular approaches to head and neck squamous cell carcinoma Anticancer drugs 22 7 2011 656 664
12. J.B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, and S. Rottey Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 11 2008 1116 1127
13. B. Vincenzi, A. Zoccoli, F. Pantano, O. Venditti, and S. Galluzzo Cetuximab: from bench to bedside Curr Cancer Drug Targets 10 1 2010 80 95
14. J.A. Bonner, P.M. Harari, J. Giralt, R.B. Cohen, C.U. Jones, and R.K. Sur Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 1 2010 21 28
15. M. Moriyama, S. Kumagai, S. Kawashiri, K. Kojima, K. Kakihara, and E. Yamamoto Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma Oral Oncol 33 5 1997 369 374 (Pubitemid 28129241)
16. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 6 2003 669 676 (Pubitemid 36749215)
17. T. Tammela, B. Enholm, K. Alitalo, and K. Paavonen The biology of vascular endothelial growth factors Cardiovasc Res 65 3 2005 550 563 (Pubitemid 40138976)
18. K. Dorsey, and M. Agulnik Promising new molecular targeted therapies in head and neck cancer Drugs 73 4 2013 315 325
19. L. Jussila, and K. Alitalo Vascular growth factors and lymphangiogenesis Phys Rev 82 3 2002 673 700 (Pubitemid 34743335)
20. M.G. Achen, G.B. Mann, and S.A. Stacker Targeting lymphangiogenesis to prevent tumour metastasis Br J Cancer 94 10 2006 1355 1360 (Pubitemid 43772266)
21. N. Rahimi VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy Front Biosci 1 11 2006 818 829 (Pubitemid 43262905)
22. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 5706 2005 58 62 (Pubitemid 40093472)
23. A. Christopoulos, S.M. Ahn, J.D. Klein, and S. Kim Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis Head Neck 33 8 2011 1220 1229
24. J.H. Harmey, and D. Bouchier-Hayes Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: Implications for anti-angiogenic therapy BioEssays 24 3 2002 280 283 (Pubitemid 34248694)
25. P. Guo, B. Hu, W. Gu, L. Xu, D. Wang, and H.J.S. Huang Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment Am J Pathol 162 4 2003 1083 1093 (Pubitemid 36350654)
26. R. Erber, A. Thurnher, A.D. Katsen, G. Groth, H. Kerger, and H.P. Hammes Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 2 2004 338 340
27. N. Choong, M. Kozloff, D. Taber, H.S. Hu, J. Wade, and P. Ivy Phase II study of sunitinib malate in head and neck squamous cell carcinoma Invest New Drugs 28 5 2010 677 683
28. J. Karar, and A. Maity Modulating the tumor microenvironment to increase radiation responsiveness Cancer Biol Ther 8 21 2009 1994 2001
29. C.J. Yeom, L. Zeng, Y. Zhu, M. Hiraoka, and H. Harada Strategies to assess hypoxic/HIF-1-active cancer cells for the development of innovative radiation therapy Cancers 3 3 2011 3610 3631
30. A.L. Kung, S. Wang, J.M. Klco, W.G. Kaelin, and D.M. Livingston Suppression of tumor growth through disruption of hypoxia-inducible transcription Nat Med 6 12 2000 1335 1340 (Pubitemid 32001016)
31. G. Bowers, D. Reardon, T. Hewitt, P. Dent, R.B. Mikkelsen, and K. Valerie The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells Oncogene 20 11 2001 1388 1397 (Pubitemid 32269943)
32. D.H. Gorski, M.A. Beckett, N.T. Jaskowiak, D.P. Calvin, H.J. Mauceri, and R.M. Salloum Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 14 1999 3374 3378 (Pubitemid 29334495)
33. J. Brieger, J. Kattwinkel, M. Berres, J. Gosepath, and W.J. Mann Impact of vascular endothelial growth factor release on radiation resistance Oncol Rep 18 2007 1597 1601
34. M.T. Sheridan, T. O'Dwyer, C.B. Seymour, and C.E. Mothersill Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck Radiat Oncol Invest 5 4 1997 180 186 (Pubitemid 27426395)
35. S. Tanno, N. Yanagawa, A. Habiro, K. Koizumi, Y. Nakano, and M. Osanai Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance Cancer Res 64 10 2004 3486 3490 (Pubitemid 38657922)
36. J.N. Ho, G.Y. Kang, S.S. Lee, J. Kim, I.H. Bae, and S.G. Hwang Bcl-XL and STAT3 mediate malignant actions of γ-irradiation in lung cancer cells Cancer Sci 101 6 2010 1417 1423
37. Z. Khan, N. Khan, R.P. Tiwari, I.K. Patro, G.B. Prasad, and P.S. Bisen Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells Radiother Oncol 96 2 2010 267 273
38. M.R. Horsman, and D.W. Siemann Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies Cancer Res 66 24 2006 11520 11539 (Pubitemid 46094158)
39. C. Timke, H. Zieher, A. Roth, K. Hauser, K.E. Lipson, and K.J. Weber Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy Clin Cancer Res 14 7 2008 2210 2219 (Pubitemid 351551134)
40. J. Hendry Treatment acceleration in radiotherapy: the relative time factors and dose-response slopes for tumours and normal tissues Radiother Oncol 25 4 1999 308 312
41. P. Vaupel Tumor microenvironmental physiology and its implications for radiation oncology Semin Radiat Oncol 14 3 2004 198 206 (Pubitemid 38903223)
42. L. Gray, A. Conger, M. Ebert, S. Hornsey, and O. Scott The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy Br J Radiol 26 312 1953 638 648
43. P. Wachsberger, R. Burd, and A.P. Dicker Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents Clin Cancer Res 9 6 2003 1957 1971 (Pubitemid 36687614)
44. R.T. Tong, Y. Boucher, S.V. Kozin, F. Winkler, D.J. Hicklin, and R.K. Jain Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 11 2004 3731 3736 (Pubitemid 38697278)
45. P.R. Wachsberger, R. Burd, N. Marero, C. Daskalakis, A. Ryan, and P. McCue Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma Clin Cancer Res 11 2 2005 835 842 (Pubitemid 40116912)
46. T. Hoang, S. Huang, E. Armstrong, J.C. Eickhoff, and P.M. Harari Enhancement of radiation response with bevacizumab J Exp Clin Cancer Res 26 2012 31 37
47. F.A. Scappaticci Mechanisms and future directions for angiogenesis-based cancer therapies J Clin Oncol 20 18 2002 3906 3927
48. R.J. Griffin, B.W. Williams, R. Wild, J.M. Cherrington, H. Park, and C.W. Song Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response Cancer Res 62 6 2002 1702 1706 (Pubitemid 34408492)
49. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342 (Pubitemid 38702844)
50. C.G. Willett, D.G. Duda, E. di Tomaso, Y. Boucher, M. Ancukiewicz, and D.V. Sahani Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary Phase II study J Clin Oncol 27 18 2009 3020 3026
51. C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, and R.T. Tong Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2 2004 145 147 (Pubitemid 38524883)
52. M.E. Van Meter, and E.S. Kim Bevacizumab: current updates in treatment Curr Opin Oncol 22 6 2010 586 591
53. A. Argiris, A.P. Kotsakis, T. Hoang, F.P. Worden, P. Savvides, and M.K. Gibson Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck Ann Oncol 24 1 2013 220 225
54. A. Bozec, A. Sudaka, J.L. Fischel, M.C. Brunstein, M.C. Etienne-Grimaldi, and G. Milano Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model Br J Cancer 99 1 2008 93 99 (Pubitemid 351920227)
55. T.Y. Seiwert, D.J. Haraf, E.E.W. Cohen, K. Stenson, M.E. Witt, and A. Dekker Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer J Clin Oncol 26 10 2008 1732 1741
56. J.K. Salama, D.J. Haraf, K.M. Stenson, E.A. Blair, M.E. Witt, and R. Williams A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers Ann Oncol 22 10 2011 2304 2309
57. J.D. Hainsworth, D.R. Spigel, F.A. Greco, D.L. Shipley, J. Peyton, and M. Rubin Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the sarah cannon oncology research consortium Cancer J 17 5 2011 267 272
58. M.G. Fury, N.Y. Lee, E. Sherman, D. Lisa, K. Kelly, and B. Lipson A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer Cancer 118 20 2012 5008 5014
59. D.S. Yoo, J.P. Kirkpatrick, O. Craciunescu, G. Broadwater, B.L. Peterson, and M.D. Carroll Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer Clin Cancer Res 18 5 2012 1404 1414
60. D. Gustafson, B. Frederick, A. Merz, and D. Raben Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts Cancer Chemother Pharmacol 61 2 2008 179 188 (Pubitemid 350160317)
61. S. Yang, J. Wu, Y. Zuo, L. Tan, H. Jia, and H. Yan ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma Curr Cancer Drug Targets 10 6 2010 611 622
62. D. Sano, F. Matsumoto, D.R. Valdecanas, M. Zhao, D.P. Molkentine, and Y. Takahashi Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro Clin Cancer Res 17 7 2011 1815 1827
63. A. Bozec, A. Sudaka, N. Toussan, J.L. Fischel, M.C. Etienne-Grimaldi, and G. Milano Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model Ann Oncol 20 10 2009 1703 1707
64. C.C.L. Tong, E.C. Ko, M.W. Sung, J.A. Cesaretti, R.G. Stock, and S.H. Packer Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases PLoS One 7 6 2012 e36979
65. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Siebels Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134 (Pubitemid 46089673)
66. V. Gupta-Abramson, A.B. Troxel, A. Nellore, K. Puttaswamy, M. Redlinger, and K. Ransone Phase II trial of sorafenib in advanced thyroid cancer J Clin Oncol 26 29 2008 4714 4719
67. C. Elser, L.L. Siu, E. Winquist, M. Agulnik, G.R. Pond, and S.F. Chin Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma J Clin Oncol 25 24 2007 3766 3773 (Pubitemid 47372619)
68. A. Yacoub, J.S. Park, L. Qiao, P. Dent, and M.P. Hagan MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion Int J Radiat Biol 77 10 2001 1067 1078 (Pubitemid 32977935)
69. H.J. Jun, M.J. Ahn, H.S. Kim, S.Y. Yi, J. Han, and S.K. Lee ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation Br J Cancer 99 1 2008 167 172 (Pubitemid 351920246)
70. A. Yadav, B. Kumar, T.N. Teknos, and P. Kumar Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins Mol Cancer Ther 10 7 2011 1241 1251
71. T.J. Kruser, D.L. Wheeler, E.A. Armstrong, M. Iida, K.R. Kozak, and A.J. van der Kogel Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors Clin Cancer Res 16 14 2010 3639 3647
72. J. Zhou, B.C. Goh, D. Albert, and C.S. Chen ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside J Hematol Oncol 2 1 2009 33 45
73. C.I. Wong, T.S. Koh, R. Soo, S. Hartono, C.H. Thng, and E. McKeegan Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies J Clin Oncol 27 28 2009 4718 4726
74. V.J. Jasinghe, Z. Xie, J. Zhou, J. Khng, L.F. Poon, and P. Senthilnathan ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft J Hepatol 49 6 2008 985 997
75. G.L. Semenza Angiogenesis ischemic and neoplastic disorders Annu Rev Med 54 1 2003 17 28
76. H.W. Hsu, D.S. Gridley, P.D. Kim, S. Hu, R. de Necochea-Campion, and R.L. Ferris Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells Oral Oncol 49 6 2013 591 597
77. P. Vaupel, S. Briest, and M. Höckel Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications Wien Med Wochenschr 152 13 2002 334 342 (Pubitemid 34824207)
78. P. Vaupel, A. Mayer, and M. Höckel Tumor hypoxia and malignant progression Methods Enzymol 381 2004 335 354 (Pubitemid 38401518)
79. S.M. Evans, and C.J. Koch Prognostic significance of tumor oxygenation in humans Cancer Lett 195 1 2003 1 16 (Pubitemid 36603331)
80. K. Toustrup, B.S. Sørensen, M. Nordsmark, M. Busk, C. Wiuf, and J. Alsner Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer Cancer Res 71 17 2011 5923 5931
81. S. Walenta, M. Wetterling, M. Lehrke, G. Schwickert, K. Sundfør, and E.K. Rofstad High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers Cancer Res 60 4 2000 916 921 (Pubitemid 30129526)
82. D.M. Brizel, T. Schroeder, R.L. Scher, S. Walenta, R.W. Clough, and M.W. Dewhirst Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer Int J Radiat Oncol 51 2 2001 349 353 (Pubitemid 32884281)
83. S. Walenta, T.V. Chau, T. Schroeder, H.A. Lehr, L.A. Kunz-Schughart, and A. Fuerst Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists? J Cancer Res Clin Oncol 129 6 2003 321 326 (Pubitemid 36963193)
84. P.A. Kyzas, I.W. Cunha, and J.P. Ioannidis Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis Clin Cancer Res 11 4 2005 1434 1440 (Pubitemid 40315223)
85. C.H. Druzgal, Z. Chen, N.T. Yeh, G.R. Thomas, F.G. Ondrey, and D.C. Duffey A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma Head Neck 27 9 2005 771 784 (Pubitemid 41266181)
86. C. Allen, S. Duffy, T. Teknos, M. Islam, Z. Chen, and P.S. Albert Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma Clin Cancer Res 13 11 2007 3182 3190 (Pubitemid 46944900)
87. T.Y. Seiwert, and E.E.W. Cohen Targeting angiogenesis in head and neck cancer Semin Oncol 35 3 2008 274 285 (Pubitemid 351787696)
88. E.E.W. Cohen, D.W. Davis, T.G. Karrison, T.Y. Seiwert, S.J. Wong, and S. Nattam Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study Lancet Oncol 10 3 2009 247 257
89. L. Farnebo, F. Jerhammar, R. Ceder, R.C. Grafström, L. Vainikka, and L. Thunell Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines J Oral Pathol Med 40 10 2011 739 746
90. Y. Huang, J. Yuan, E. Righi, W.S. Kamoun, M. Ancukiewicz, and J. Nezivar Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy Proc Natl Acad Sci USA 109 43 2012 17561 17566
91. Y. Huang, S. Goel, D.G. Dual, D. Fukumura, and R.K. Jain Vascular normalization as an emerging strategy to enhance cancer immunotherapy Cancer Res 73 10 2013 2943 2948
92. R. Hlushchuk, A.N. Makanya, and V. Djonov Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again? Int J Dev Biol 55 2011 563 567
93. R. Hlushchuk, O. Riesterer, O. Baum, J. Wood, G. Gruber, and M. Pruschy Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation Am J Pathol 173 2008 1173 1185
94. R. Hlushchuk, O. Baum, G. Gruber, J. Wood, and V. Djonov The synergistic action of a VEGF-receptor tyrosine-kinase inhibitor and a sensitizing PDGF-receptor blocker depends upon the stage of vascular maturation Micro Circulation 14 2007 813 825 (Pubitemid 350131389)
95. B. Sennino, F. Kuhnert, S.P. Tabruyn, M.R. Mancuso, D.D. Hu-Lowe, and C.J. Kuo Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors Cancer Res 69 2009 4527 4536
96. I. Helfrich, I. Scheffrahn, S. Bartling, J. Weis, F.V. Von, and M. Middleton Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma J Exp Med 207 2010 491 503
97. T.T. Batchelor, A.G. Sorensen, T.E. Di, W.T. Zhang, D.G. Duda, and K.S. Cohen AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95 (Pubitemid 46075199)